delphistem is pleased to announce that its Co-Founder and Chief Scientific Officer, Dr. Noel Moya, PhD, has been selected to serve as a scientific peer reviewer for the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs.
Dr. Moya will participate in the NIH study section focused on Endocrinology, Diabetes, Metabolism, and Obesity, contributing his scientific expertise to the evaluation of innovative biomedical research proposals.
The NIH SBIR/STTR programs, collectively known as America's Seed Fund, support early-stage research and development by small businesses, helping advance promising scientific discoveries toward commercialization and real-world applications.
With extensive experience in stem cell biology, regenerative medicine, and diabetes research, Dr. Moya brings a scientific perspective grounded in both academic research and biotechnology innovation.
"Scientific breakthroughs require more than great ideas. They need rigorous evaluation, funding, and the opportunity to translate promising research into real-world impact," said Dr. Moya. "I'm grateful for the opportunity to contribute my expertise to this process and help advance the next generation of biomedical innovation."
At delphistem, Dr. Moya leads the scientific development of a personalized regenerative cell therapy aimed at restoring insulin production in people living with Type 1 diabetes.
His selection for NIH peer-review service reflects his continued engagement with the broader scientific community and his commitment to advancing biomedical innovation.
About delphistem
delphistem is an Atlanta-based biotechnology company developing personalized regenerative medicine therapies with the goal of restoring natural function (not managing disease) with an initial focus on diabetes.
